CME Group shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell and announced a $195 price target.
Portfolio Pulse from Benzinga Newsdesk
CME Group's stock trades lower following a downgrade from Neutral to Sell by Goldman Sachs, which also set a price target of $195.
January 03, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CME Group's stock is likely to experience downward pressure in the short term due to the downgrade by Goldman Sachs and the new price target of $195.
Analyst downgrades typically lead to a negative perception among investors, potentially causing a sell-off. The new price target of $195 by Goldman Sachs suggests a bearish outlook on the stock's value, which could further influence investor sentiment and stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100